Zs Pharma Inc. (ZSPH) 42.50 $ZSPH
ZS Pharma Announces Publications in Peer-Reviewed Medical Journals
GlobeNewswire - Wed Apr 15, 4:02PM CDT
-- NEJM letter to the Editor highlights rapid efficacy in patients with severe hyperkalemia -
ZSPH: 42.50 (+1.08)
Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019 - Increase in Associated Disorders with CKD
M2 - Tue Apr 07, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ft8dbw/global_chronic) has announced the addition of the "Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019" report to their offering. The Global CKD Drugs market to grow at a CAGR of 1.21% over the period 2014-2019 According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration. Approval of new pipelines drugs is one of the key trends being witnessed in this market. The approval of new products gives motivation to the market players and directs their focus toward R&D and innovation. The launch of three new pipeline drugs, ferric citrate, Omontys (peginesatide), and Nulojix (belatacept), is expected to boost the market. According to the report, the Global CKD Drugs market is predominantly driven by an increase in associated disorders such as hypertension and diabetes, an increase in the aging population, and unmet needs and side effects. The chance of having CKD increases with age and is most common among those aged over 65 years. Further, the report states that the major challenge faced by Global CKD Drugs market is the genericization of major brands. This will create space for generic drug manufacturers. Branded CKD drugs are also exempted from Medicare coverage, resulting in patient incompliance. Key Vendors - Actavis PLC - Amgen Inc. - Johnson & Johnson - F. Hoffmann-La Roche Ltd - Sanofi Other Prominent Vendors - Abbott Laboratories - Akebia Therapeutics - AMAG Pharmaceuticals - Cara Therapeutics - FibroGen - Keryx Biopharmaceuticals - Reata Pharmaceuticals - OPKO Health - Pharmacosmos - Raptor Pharmaceuticals - Regulus Therapeutics - Rockwell Medical - Shield Therapeutics - Takeda Pharmaceuticals - Vifor Pharma Ltd - Xenetic Biosciences - ZS Pharma For more information visit http://www.researchandmarkets.com/research/ft...al_chronic
JNJ: 100.43 (+0.13), ABT: 48.35 (+1.23), ZSPH: 42.50 (+1.08), RPTP: 10.56 (-0.17), OPK: 14.60 (+0.17), AMGN: 169.10 (+0.64), RGLS: 17.40 (-0.22), AMAG: 57.68 (+0.47), AKBA: 8.39 (+0.07), KERX: 11.52 (-0.15)
ZS Pharma (ZSPH) Crumbles: Stock Falls by 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 7:57AM CDT
ZS Pharma fell nearly 10% in the last trading session, continuing its recent downtrend
LCI: 66.45 (-0.28), ZSPH: 42.50 (+1.08)
ZS Pharma sets the price and upsizes equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 6:36AM CDT
ZSPH: 42.50 (+1.08)
ZS Pharma Announces Upsizing and Pricing of $186 Million Public Offering of Common Stock
GlobeNewswire - Tue Mar 24, 11:46PM CDT
ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced the upsizing and pricing of its underwritten public offering. The size of the offering has been increased from the previously announced 3,300,000 shares of common stock to 4,015,939 shares of common stock. The shares are being offered to the public at a price of $46.25 per share, resulting in aggregate proceeds to the Company of $185.7 million before underwriting discounts and expenses. In addition, a single selling stockholder, Alta Partners VIII, L.P., has granted the underwriters a 30-day option to purchase up to 602,390 additional shares of the Company's common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on March 30, 2015, subject to customary closing conditions.
ZSPH: 42.50 (+1.08), JPM: 62.94 (+0.63)
ZS Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:45PM CDT
ZSPH: 42.50 (+1.08)
ZS Pharma Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Mar 23, 3:13PM CDT
ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that it intends to offer and sell, subject to market and other conditions 3,300,000 shares of its common stock in an underwritten public offering. A single selling stockholder, Alta Partners VIII, L.P., expects to grant the underwriters a 30-day option to purchase up to 495,000 additional shares of the Company's common stock.
ZSPH: 42.50 (+1.08), JPM: 62.94 (+0.63)
ZS Pharma to Present Data From Phase 3 Trials of ZS-9 in Presentations at the National Kidney Foundation 2015 Spring Clinical Meetings
GlobeNewswire - Thu Mar 19, 7:00AM CDT
ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that data from Phase 3 trials of ZS-9 (sodium zirconium cyclosilicate), an investigational treatment for hyperkalemia, will be presented at the National Kidney Foundation 2015 Spring Clinical Meetings being held March 25 to 29, 2015 in Dallas, Texas. The Company is also sponsoring a medical education symposium to review emerging treatments of hyperkalemia in chronic kidney disease.
ZSPH: 42.50 (+1.08)
ZS Pharma Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 8:38AM CDT
ZSPH: 42.50 (+1.08)
ZS Pharma misses by $0.23
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 6:20AM CDT
ZSPH: 42.50 (+1.08)
ZS Pharma Reports Fourth Quarter and Year-End 2014 Financial Results and Provides ZS-9 Program Update
GlobeNewswire - Fri Mar 13, 6:00AM CDT
ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today provided a program update on ZS-9 (sodium zirconium cyclosilicate), the Company's investigational treatment for hyperkalemia, and reported its financial results for the fourth quarter and year ended December 31, 2014.
ZSPH: 42.50 (+1.08)
IPO Stock Watch: Biotech ZS Pharma Hits New High
at Investor's Business Daily - Fri Feb 20, 4:50PM CST
ZS Pharma (ZSPH) hit a new high Friday, following the appointment of several new executives that will help the biotech company prepare for drug trials. The biopharmaceutical company is focused on developing and commercializing drugs to treat renal,...
ZSPH: 42.50 (+1.08)
ZS Pharma Hires Key Medical Affairs and Commercial Executives
GlobeNewswire - Thu Feb 19, 7:07AM CST
- As ZS-9 Nears NDA and MAA Submissions, ZS Pharma Adds Key Members to Its Medical Affairs and Commercial Leadership Team -
ZSPH: 42.50 (+1.08)
ZS Pharma names Martin Babler to board
M2 - Wed Feb 11, 4:12AM CST
Biopharmaceutical company ZS Pharma (NasdaqGM:ZSPH) revealed on Tuesday that Martin Babler has been appointed to its board of directors.
ZSPH: 42.50 (+1.08)
ZS Pharma Appoints Martin Babler to Board of Directors
GlobeNewswire - Tue Feb 10, 3:00PM CST
ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that Martin Babler, Chief Executive Officer of Principia Biopharma, has been appointed to the ZS Pharma Board of Directors. Mr. Babler brings significant commercialization experience to ZS Pharma as sodium zirconium cyclosilicate (ZS-9), the Company's novel drug candidate for hyperkalemia, nears NDA and MAA submission.
ZSPH: 42.50 (+1.08)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 4.01 (-0.06), INSM: 23.12 (-0.10), RNN: 0.73 (-0.03), ZSPH: 42.50 (+1.08), RDHL: 14.61 (+0.05), ASPX: 100.79 (+0.09), ACUR: 0.75 (-0.03), XNPT: 7.42 (+0.12), SPNC: 34.65 (-0.07), CORI: 9.09 (+0.42), SAGE: 59.50 (-2.56), EBIO: 10.32 (+0.22), HAE: 42.33 (-0.21), JAZZ: 186.13 (-0.41), ICPT: 280.45 (-8.26), NVDQ: 12.43 (-0.37)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.62 (-0.09), ACT: 295.22 (+0.69), VRX: 206.93 (-3.92), PCYC: 256.98 (-0.77), ZSPH: 42.50 (+1.08), RMTI: 10.82 (+0.13), BCLI: 4.29 (-0.09), SIEN: 16.45 (-0.22), JNJ: 100.43 (+0.13), ECYT: 6.37 (unch), SNY: 51.59 (+0.03), LENS: 8.00 (+0.63), REGN: 472.63 (+9.41), SYK: 96.45 (+1.74), PFE: 34.93 (+0.04), SLXP: 172.96 (+0.15), AMGN: 169.10 (+0.64), APPY: 0.56 (-0.14), MNKD: 4.90 (-0.09), CELG: 115.54 (+0.72), ISRG: 516.93 (-29.80), GILD: 104.18 (-1.02), ANIP: 69.79 (+1.24), MRK: 57.69 (+0.03), ALXN: 188.19 (+1.41), CCXI: 7.86 (-0.02), ICPT: 280.45 (-8.26), AEZS: 0.60 (-0.03), ATRS: 2.78 (unch), NASH: 33.12 (+0.48)
ZS Pharma:: A Few Months Behind, But An Inpatient Advantage
Investing Doc - at Seeking Alpha - Thu Jan 29, 7:02AM CST
ZSPH: 42.50 (+1.08), RLYP: 35.39 (-0.54)
ZS Pharma to Present at J.P. Morgan Healthcare Conference
GlobeNewswire - Tue Jan 06, 7:07AM CST
ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that management will present at the J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, Calif., on Tuesday, January 13, 2015, at 2:30 p.m. PT.
ZSPH: 42.50 (+1.08), JPM: 62.94 (+0.63)
InsiderInsights.com Daily Round Up 12/17/14: HTZ, NAV, ENH, AIRT
InsiderInsights - at Seeking Alpha - Thu Dec 18, 3:35AM CST
CNXR: 11.90 (-0.52), HTZ: 21.38 (+0.31), ZSPH: 42.50 (+1.08), ISIG: 3.03 (+0.03), WMS: 28.56 (+0.53), AIRT: 21.60 (-0.64), MAR: 80.79 (+0.32), RL: 136.39 (+0.44), ADBE: 75.50 (+0.88), CI: 130.25 (-0.45), AMH: 17.10 (unch), WIW: 11.45 (unch), NOW: 77.72 (+0.22), SGEN: 36.92 (-0.32), BEAV: 63.43 (-0.01), NAV: 29.89 (+0.41), AGIO: 103.51 (-4.12), AI: 23.70 (-0.25), ENH: 61.61 (+0.22)
ZS Pharma Announces Publications in Peer-Reviewed Medical Journals
GlobeNewswire - Wed Apr 15, 4:02PM CDT
-- NEJM letter to the Editor highlights rapid efficacy in patients with severe hyperkalemia -
ZSPH: 42.50 (+1.08)
Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019 - Increase in Associated Disorders with CKD
M2 - Tue Apr 07, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ft8dbw/global_chronic) has announced the addition of the "Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019" report to their offering. The Global CKD Drugs market to grow at a CAGR of 1.21% over the period 2014-2019 According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration. Approval of new pipelines drugs is one of the key trends being witnessed in this market. The approval of new products gives motivation to the market players and directs their focus toward R&D and innovation. The launch of three new pipeline drugs, ferric citrate, Omontys (peginesatide), and Nulojix (belatacept), is expected to boost the market. According to the report, the Global CKD Drugs market is predominantly driven by an increase in associated disorders such as hypertension and diabetes, an increase in the aging population, and unmet needs and side effects. The chance of having CKD increases with age and is most common among those aged over 65 years. Further, the report states that the major challenge faced by Global CKD Drugs market is the genericization of major brands. This will create space for generic drug manufacturers. Branded CKD drugs are also exempted from Medicare coverage, resulting in patient incompliance. Key Vendors - Actavis PLC - Amgen Inc. - Johnson & Johnson - F. Hoffmann-La Roche Ltd - Sanofi Other Prominent Vendors - Abbott Laboratories - Akebia Therapeutics - AMAG Pharmaceuticals - Cara Therapeutics - FibroGen - Keryx Biopharmaceuticals - Reata Pharmaceuticals - OPKO Health - Pharmacosmos - Raptor Pharmaceuticals - Regulus Therapeutics - Rockwell Medical - Shield Therapeutics - Takeda Pharmaceuticals - Vifor Pharma Ltd - Xenetic Biosciences - ZS Pharma For more information visit http://www.researchandmarkets.com/research/ft...al_chronic
JNJ: 100.43 (+0.13), ABT: 48.35 (+1.23), ZSPH: 42.50 (+1.08), RPTP: 10.56 (-0.17), OPK: 14.60 (+0.17), AMGN: 169.10 (+0.64), RGLS: 17.40 (-0.22), AMAG: 57.68 (+0.47), AKBA: 8.39 (+0.07), KERX: 11.52 (-0.15)
ZS Pharma (ZSPH) Crumbles: Stock Falls by 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 7:57AM CDT
ZS Pharma fell nearly 10% in the last trading session, continuing its recent downtrend
LCI: 66.45 (-0.28), ZSPH: 42.50 (+1.08)
ZS Pharma sets the price and upsizes equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 6:36AM CDT
ZSPH: 42.50 (+1.08)
ZS Pharma Announces Upsizing and Pricing of $186 Million Public Offering of Common Stock
GlobeNewswire - Tue Mar 24, 11:46PM CDT
ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced the upsizing and pricing of its underwritten public offering. The size of the offering has been increased from the previously announced 3,300,000 shares of common stock to 4,015,939 shares of common stock. The shares are being offered to the public at a price of $46.25 per share, resulting in aggregate proceeds to the Company of $185.7 million before underwriting discounts and expenses. In addition, a single selling stockholder, Alta Partners VIII, L.P., has granted the underwriters a 30-day option to purchase up to 602,390 additional shares of the Company's common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on March 30, 2015, subject to customary closing conditions.
ZSPH: 42.50 (+1.08), JPM: 62.94 (+0.63)
ZS Pharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:45PM CDT
ZSPH: 42.50 (+1.08)
ZS Pharma Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Mar 23, 3:13PM CDT
ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that it intends to offer and sell, subject to market and other conditions 3,300,000 shares of its common stock in an underwritten public offering. A single selling stockholder, Alta Partners VIII, L.P., expects to grant the underwriters a 30-day option to purchase up to 495,000 additional shares of the Company's common stock.
ZSPH: 42.50 (+1.08), JPM: 62.94 (+0.63)
ZS Pharma to Present Data From Phase 3 Trials of ZS-9 in Presentations at the National Kidney Foundation 2015 Spring Clinical Meetings
GlobeNewswire - Thu Mar 19, 7:00AM CDT
ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that data from Phase 3 trials of ZS-9 (sodium zirconium cyclosilicate), an investigational treatment for hyperkalemia, will be presented at the National Kidney Foundation 2015 Spring Clinical Meetings being held March 25 to 29, 2015 in Dallas, Texas. The Company is also sponsoring a medical education symposium to review emerging treatments of hyperkalemia in chronic kidney disease.
ZSPH: 42.50 (+1.08)
ZS Pharma Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 8:38AM CDT
ZSPH: 42.50 (+1.08)
ZS Pharma misses by $0.23
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 6:20AM CDT
ZSPH: 42.50 (+1.08)
ZS Pharma Reports Fourth Quarter and Year-End 2014 Financial Results and Provides ZS-9 Program Update
GlobeNewswire - Fri Mar 13, 6:00AM CDT
ZS Pharma, Inc. (Nasdaq:ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today provided a program update on ZS-9 (sodium zirconium cyclosilicate), the Company's investigational treatment for hyperkalemia, and reported its financial results for the fourth quarter and year ended December 31, 2014.
ZSPH: 42.50 (+1.08)
IPO Stock Watch: Biotech ZS Pharma Hits New High
at Investor's Business Daily - Fri Feb 20, 4:50PM CST
ZS Pharma (ZSPH) hit a new high Friday, following the appointment of several new executives that will help the biotech company prepare for drug trials. The biopharmaceutical company is focused on developing and commercializing drugs to treat renal,...
ZSPH: 42.50 (+1.08)
ZS Pharma Hires Key Medical Affairs and Commercial Executives
GlobeNewswire - Thu Feb 19, 7:07AM CST
- As ZS-9 Nears NDA and MAA Submissions, ZS Pharma Adds Key Members to Its Medical Affairs and Commercial Leadership Team -
ZSPH: 42.50 (+1.08)
ZS Pharma names Martin Babler to board
M2 - Wed Feb 11, 4:12AM CST
Biopharmaceutical company ZS Pharma (NasdaqGM:ZSPH) revealed on Tuesday that Martin Babler has been appointed to its board of directors.
ZSPH: 42.50 (+1.08)
ZS Pharma Appoints Martin Babler to Board of Directors
GlobeNewswire - Tue Feb 10, 3:00PM CST
ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that Martin Babler, Chief Executive Officer of Principia Biopharma, has been appointed to the ZS Pharma Board of Directors. Mr. Babler brings significant commercialization experience to ZS Pharma as sodium zirconium cyclosilicate (ZS-9), the Company's novel drug candidate for hyperkalemia, nears NDA and MAA submission.
ZSPH: 42.50 (+1.08)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 4.01 (-0.06), INSM: 23.12 (-0.10), RNN: 0.73 (-0.03), ZSPH: 42.50 (+1.08), RDHL: 14.61 (+0.05), ASPX: 100.79 (+0.09), ACUR: 0.75 (-0.03), XNPT: 7.42 (+0.12), SPNC: 34.65 (-0.07), CORI: 9.09 (+0.42), SAGE: 59.50 (-2.56), EBIO: 10.32 (+0.22), HAE: 42.33 (-0.21), JAZZ: 186.13 (-0.41), ICPT: 280.45 (-8.26), NVDQ: 12.43 (-0.37)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.62 (-0.09), ACT: 295.22 (+0.69), VRX: 206.93 (-3.92), PCYC: 256.98 (-0.77), ZSPH: 42.50 (+1.08), RMTI: 10.82 (+0.13), BCLI: 4.29 (-0.09), SIEN: 16.45 (-0.22), JNJ: 100.43 (+0.13), ECYT: 6.37 (unch), SNY: 51.59 (+0.03), LENS: 8.00 (+0.63), REGN: 472.63 (+9.41), SYK: 96.45 (+1.74), PFE: 34.93 (+0.04), SLXP: 172.96 (+0.15), AMGN: 169.10 (+0.64), APPY: 0.56 (-0.14), MNKD: 4.90 (-0.09), CELG: 115.54 (+0.72), ISRG: 516.93 (-29.80), GILD: 104.18 (-1.02), ANIP: 69.79 (+1.24), MRK: 57.69 (+0.03), ALXN: 188.19 (+1.41), CCXI: 7.86 (-0.02), ICPT: 280.45 (-8.26), AEZS: 0.60 (-0.03), ATRS: 2.78 (unch), NASH: 33.12 (+0.48)
ZS Pharma:: A Few Months Behind, But An Inpatient Advantage
Investing Doc - at Seeking Alpha - Thu Jan 29, 7:02AM CST
ZSPH: 42.50 (+1.08), RLYP: 35.39 (-0.54)
ZS Pharma to Present at J.P. Morgan Healthcare Conference
GlobeNewswire - Tue Jan 06, 7:07AM CST
ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that management will present at the J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, Calif., on Tuesday, January 13, 2015, at 2:30 p.m. PT.
ZSPH: 42.50 (+1.08), JPM: 62.94 (+0.63)
InsiderInsights.com Daily Round Up 12/17/14: HTZ, NAV, ENH, AIRT
InsiderInsights - at Seeking Alpha - Thu Dec 18, 3:35AM CST
CNXR: 11.90 (-0.52), HTZ: 21.38 (+0.31), ZSPH: 42.50 (+1.08), ISIG: 3.03 (+0.03), WMS: 28.56 (+0.53), AIRT: 21.60 (-0.64), MAR: 80.79 (+0.32), RL: 136.39 (+0.44), ADBE: 75.50 (+0.88), CI: 130.25 (-0.45), AMH: 17.10 (unch), WIW: 11.45 (unch), NOW: 77.72 (+0.22), SGEN: 36.92 (-0.32), BEAV: 63.43 (-0.01), NAV: 29.89 (+0.41), AGIO: 103.51 (-4.12), AI: 23.70 (-0.25), ENH: 61.61 (+0.22)
